Earlier this full year, the MEVION S250 received CE certification, which gives Mevion the ability to market, offer, import, and install proton therapy systems in the European Union and other regions where the CE Marking is recognized.. AMS announces FDA clearance of MEVION S250 Proton Therapy System AMERICAN SHARED HOSPITAL SERVICES , a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, shared a recently available announcement from Mevion Medical today Systems, Inc. Regarding Mevion Medical Systems’ receipt of FDA 510 clearance because of its MEVION S250 Proton Therapy System.The number of patients whose disease progressed to the accelerated phase or a blast crisis within 24 months were similar among the four groups. Those affected had been four individuals receiving imatinib only at a dosage of 400 mg, five patients receiving imatinib by itself at a dose of 600 mg, four individuals getting imatinib and cytarabine, and five individuals getting imatinib and peginterferon alfa-2a. Discussion In this randomized study, we compared imatinib at the typical dose of 400 mg with an increased dose of imatinib or a combined mix of imatinib with cytarabine or peginterferon alfa-2a as treatment for newly diagnosed, chronic-phase CML. Based on the marked differences between your combined groups, particularly with regards to the rates of superior molecular response, the independent data and safety monitoring plank recommended that the info be disclosed.